Half Title Page.
1: Basic Principles and Methodlogy.
2: Modern Cancer Drug Discovery.
3: Pharmacogenomics and Personalized Medicines in Cancer Treatment.
4: Natural Product Chemistry and Cancer Drug Discovery.
5: Structural Biology and Anticancer Drug Design.
6: Drugs in the Laboratory and Clinic.
7: Temozolomide: From Cytotoxic to Molecularly Targeted Agent.
8: Temozolomide: Patents and the Perils of Invention.
9: A New Generation of Cell-Targeted Drugs for Cancer Treatment.
10: Inhibition of DNA Repair as a Therapeutic Target.
11: Exploiting Cancer Dependence on Molecular Chaperones: HSP90 Inhibitors Past, Present, and Future.
12: Inhibitors of Tumor Angiogenesis.
13: The Renaissance of CYP17 Inhibitors for the Treatment of Prostate Cancer.
14: Apoptosis in Cancer: Mechanisms, Deregulation, and Therapeutic Targeting.
15: Targeting the MDM2–p53 Protein–Protein Interaction: Design, Discovery, and Development of Novel Anticancer Agents.
16: Targeting Altered Metabolism—Emerging Cancer Therapeutic Strategies.
17: Inhibitors of the Phosphatidylinositol 3-Kinase Pathway.
18: Antibody–Drug Conjugates Delivering DNA Cytotoxics.
19: Inhibition of Telomerase.
20: Targeting B-RAF: The Discovery and Development of B-RAF Inhibitors.
21: The Reality of Cancer Drugs in the Clinic.
22: Failure Modes in Anticancer Drug Discovery and Development.
23: Anticancer Drug Registration and Regulation:Current Challenges and Possible Solutions.